Differences in scoring criteria for gastric versus breast cancer, interlaboratory heterogeneity, and limited confirmatory testing contribute to inconsistent HER2 classification, directly affecting trial eligibility and potentially explaining variations in response rates across global studies. Here, ERBB2 is linked to breast carcinoma.